AURA Stock Forecast: Aura Biosciences, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$6.87
−1.58% on the day

The 6 Wall Street analysts covering Aura Biosciences, Inc. hold a median 12-month price target of $15 — +118.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 61 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$715.0M
Ticker Nerd rank
61/ 100
Median analyst target
$15
Analysts covering
6
Revenue$0.0
Operating income−$48.1M
Net income−$45.6M
Free cash flow−$32.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.4%
1M
+4.7%
YTD
+26.1%
1Y
+28.4%
From 52W high
−22.8%
From 52W low
+38.2%
$4.97
$8.90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Aura Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
61/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
81
Value
71
Revisions
64
Accruals
59
Momentum
58
Quality
47
Growth
45
Issuance
35

Volatility (81): The share price has been relatively steady.

Issuance (35): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AURA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AURA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00$25.00Jan 26Apr 26Jul 26Oct 26AURAHigh $23Median $15Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6
Buy
0
Hold
0
Sell
$12
Low
$15
Median
$23
High

The green dot is the last close — the median target sits +118.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Aug 2026HC Wainwright & Co.MaintainsBuy$24 → $18
29 Apr 2026HC Wainwright & Co.MaintainsBuy$22 → $24
30 Mar 2026HC Wainwright & Co.ReiteratesBuy—
26 Nov 2025Evercore ISI GroupReinstatesOutperform$13
13 Aug 2025HC Wainwright & Co.ReiteratesBuy—
28 May 2025HC Wainwright & Co.AssumesBuy$22
23 May 2025JMP SecuritiesReiteratesMarket Outperform—
26 Mar 2025Citizens Capital MarketsMaintainsMarket Outperform—
26 Mar 2025JMP SecuritiesMaintainsMarket Outperform—
25 Mar 2025HC Wainwright & Co.MaintainsBuy—
24 Mar 2025HC Wainwright & Co.ReiteratesBuy—
5 Dec 2024JMP SecuritiesMaintainsMarket Outperform—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
18 Oct 2024BTIGMaintainsBuy—
18 Oct 2024HC Wainwright & Co.MaintainsBuy—
18 Oct 2024ScotiabankMaintainsSector Outperform—
13 Sept 2024HC Wainwright & Co.ReiteratesBuy—
13 Sept 2024JMP SecuritiesMaintainsMarket Outperform—
28 Aug 2024JMP SecuritiesReiteratesMarket Outperform—
25 July 2024HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for AURA.

Market Radar

This page is one stock. Monday covers all of them.

AURA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

AURA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Aura Biosciences, Inc. returned +28.4% against +6.9% for the S&P 500, dividends included.

AURA vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160Jan 26Apr 26Jul 26Oct 26AURAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AURA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
3
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
2.5×

Cheaper than 36% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−61.7%

Higher than 19% of US stocks

Return on assets
−35.5%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aura Biosciences, Inc. has a market value of $715.0M and an enterprise value of $433.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$131.0M.

  • Free cash flow in the twelve months to 30 June 2026: −$103.4M.

  • Shares outstanding: 103.4M.

  • Aura Biosciences, Inc. employs 113 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

AURA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AURAAura Biosciences, Inc.$715.0M61
SLDBSolid Biosciences, Inc.$697.6M43
GLUEMonte Rosa Therapeutics, Inc.$729.9M48
ATTOAttovia Therapeutics, Inc.$688.2M4
OBXObsidian Therapeutics, Inc.$740.7M36
LXRXLexicon Pharmaceuticals, Inc.$680.8M69
RIGLRigel Pharmaceuticals, Inc.$741.7M84

Take a look at AURA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Aura Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about AURA

What is the AURA stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Aura Biosciences, Inc. have a median 12-month price target of $15, with estimates ranging from $12 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AURA stock a buy right now?

Of the 6 analysts covering Aura Biosciences, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aura Biosciences, Inc. 61 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AURA?

As at 21 Nov 2026, Aura Biosciences, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (81 of 100).

Will AURA stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +118.3% from the last close, and Ticker Nerd's factor model ranks Aura Biosciences, Inc. 61 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AURA stock forecast for 2030?

No analyst covering Aura Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AURA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $23 over the next 12 months.

How has AURA stock performed over the past year?

Aura Biosciences, Inc. returned +28.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aura Biosciences, Inc. do?

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors, with a particular emphasis on ocular cancers. Its lead program centers on belzupacap sarotalocan, a virus-like drug conjugate designed to selectively target cancer cells while preserving healthy tissue and organ function.

Company

About Aura Biosciences, Inc.

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors, with a particular emphasis on ocular cancers. Its lead program centers on belzupacap sarotalocan, a virus-like drug conjugate designed to selectively target cancer cells while preserving healthy tissue and organ function. The company’s platform is built around virus-like particles that deliver therapeutic payloads directly to tumors and support an immune response against cancer. Aura Biosciences is advancing its oncology pipeline across ocular oncology and other related indications, including bladder cancer, using a targeted approach intended for specialist treatment settings. Headquartered in Boston, Massachusetts, Aura Biosciences plays a focused role in the biotechnology market as a developer of novel cancer therapies for hard-to-treat solid tumors.

CEO Ms. Natalie C. Holles · 113 employees · United States · https://www.aurabiosciences.com